|Stage of funding:||Current|
|Therapeutic group:||Inflammatory Diseases|
Celtaxsys is a clinical-stage development company focused on novel therapeutics that treat inflammatory disease through regulation of immune cell migration and activation. The company is building a sustainable pipeline of first-in-class immuno-modulators .
The lead drug candidate, CTX-4430, is a potent, oral, once-daily, small-molecule LTA4 Hydrolase (LTA4H) inhibitor – the key enzyme in the production of the powerful promoter of inflammation Leukotriene B4 (LTB4). Both LTA4H and LTB4 are strongly implicated in the pathogenesis of pulmonary inflammation in Cystic Fibrosis (CF). CTX-4430 has been shown to be effective in several CF-related, pre-clinical and clinical models and has been well tolerated in healthy volunteers and CF patients.
CTX-4430 will also be advanced into a phase II trial in moderately severe acne, a disorder characterized by a high expression of LTB4. It is one of a series of candidates covered under composition of matter patents being developed by Celtaxsys.
Celtaxsys is located in Atlanta, GA with a subsidiary office in Brisbane, Queensland, Australia.
Neothetics, Inc. (NASDAQ:NEOT) today provided a business update and reported financial results for the fourth quarter 2016. “We are encouraged by our progress on our Phase 2 proof of concept trial for LIPO-202 in submental fat reduction and continue to expect top-line data in June 2017,” said Mr. Jeffrey M. Nugent, a member of Neothetics’ Operating Committee and Board of Directors.
20 March 2017
17 March 2017
14 March 2017